Takeda Pharmaceutical Co. (TAK)
(Real Time Quote from BATS)
$13.30 USD
+0.01 (0.08%)
Updated Nov 21, 2024 03:02 PM ET
5-Strong Sell of 5 5
A Value C Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TAK 13.30 +0.01(0.08%)
Will TAK be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
TAK or CTLT: Which Is the Better Value Stock Right Now?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
Other News for TAK
Takeda in deal with Alloy Therapeutics to develop cell therapy platforms for cancer
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
Biotech Alert: Searches spiking for these stocks today